Valneva has been granted a patent for a process to produce an immunogenic live attenuated Chikungunya virus and pharmaceutical compositions containing it. The patent includes a claim for a pharmaceutical composition comprising specific CHIKV-?5nsP3 particles expressing E2 structural proteins with defined mutations. GlobalData’s report on Valneva gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Valneva, Anti-viral antigen-based compositions was a key innovation area identified from patents. Valneva's grant share as of May 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
Live attenuated chikungunya virus vaccine
A recently granted patent (Publication Number: US12011477B2) discloses a pharmaceutical composition containing CHIKV-?5nsP3 particles that express an E2 structural protein. The composition includes a specific number of particles expressing the E2 protein as defined by a particular amino acid sequence, along with particles expressing the protein with one to ten mutations compared to the reference sequence. These mutations can impact the immunogenicity of the particles, with the composition containing varying percentages of mutated particles.
Furthermore, the patented pharmaceutical composition is designed to induce neutralizing antibodies against CHIKV-?5nsP3 in mice, resulting in serum that can neutralize Chikungunya virus infection in vitro. The composition is obtained through a specific production process involving passaging the particles on Vero cells in culture a limited number of times. Additionally, the composition can be administered as a one-shot vaccine, formulated in a lyophilized form for subcutaneous administration, and includes pharmaceutically acceptable excipients. The patent also covers a method for protecting against Chikungunya virus disease by administering this pharmaceutical composition to a subject in need, particularly focusing on human subjects.
To know more about GlobalData’s detailed insights on Valneva, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
